Language:

High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme

Esparza, Thomas J ; Martin, Negin P ; Anderson, George P ; Goldman, Ellen R ; Brody, David L

Scientific reports, 2020-12, Vol.10 (1), p.22370-13, Article 22370 [Peer Reviewed Journal]

England: Nature Publishing Group

Full text available

Citations Cited by

Actions
1. Add to e-Shelf
2. Remove from e-Shelf
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme
Author: Esparza, Thomas J ; Martin, Negin P ; Anderson, George P ; Goldman, Ellen R ; Brody, David L
Subjects: ACE2 ; Affinity ; Angiotensin ; Angiotensin-converting enzyme 2 ; Angiotensin-Converting Enzyme 2 - genetics ; Angiotensin-Converting Enzyme 2 - metabolism ; Animals ; Antibodies, Neutralizing - immunology ; Antibodies, Viral - immunology ; Antibody Affinity ; Binding Sites, Antibody - immunology ; Camelids, New World ; COVID-19 ; COVID-19 - metabolism ; COVID-19 - therapy ; COVID-19 - virology ; Drug Discovery - methods ; Enzymes ; HEK293 Cells ; Humans ; Immunization - methods ; Inhalation ; Male ; Nanobodies ; Pandemics ; Peptidyl-dipeptidase A ; Protein Binding ; Protein Interaction Domains and Motifs - immunology ; Proteins ; SARS-CoV-2 - chemistry ; Severe acute respiratory syndrome coronavirus 2 ; Signal Transduction - genetics ; Single-Domain Antibodies - immunology ; Spike Glycoprotein, Coronavirus - chemistry ; Spike Glycoprotein, Coronavirus - genetics ; Spike protein ; Transduction, Genetic ; Transfection
Is Part Of: Scientific reports, 2020-12, Vol.10 (1), p.22370-13, Article 22370
Description: There are currently few approved effective treatments for SARS-CoV-2, the virus responsible for the COVID-19 pandemic. Nanobodies are 12-15 kDa single-domain antibody fragments that can be delivered by inhalation and are amenable to relatively inexpensive large scale production compared to other biologicals. We have isolated nanobodies that bind to the SARS-CoV-2 spike protein receptor binding domain and block spike protein interaction with the angiotensin converting enzyme 2 (ACE2) with 1-5 nM affinity. The lead nanobody candidate, NIH-CoVnb-112, blocks SARS-CoV-2 spike pseudotyped lentivirus infection of HEK293 cells expressing human ACE2 with an EC of 0.3 µg/mL. NIH-CoVnb-112 retains structural integrity and potency after nebulization. Furthermore, NIH-CoVnb-112 blocks interaction between ACE2 and several high affinity variant forms of the spike protein. These nanobodies and their derivatives have therapeutic, preventative, and diagnostic potential.
Publisher: England: Nature Publishing Group
Language: English

Links

View this record in MEDLINE/PubMed

Back to results list

Previous Result 9 Next Go to Next page

Implemented by: Social Network Logos:

High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme

Esparza, Thomas J ; Martin, Negin P ; Anderson, George P ; Goldman, Ellen R ; Brody, David L

England: Nature Publishing Group

Searching Remote Databases, Please Wait